Clinical Trial Search

Primary: Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma. — 0; 0…

Primary: Overall Response Rate (ORR) — 0; 6; 6 Participants

Primary: Progression-free Survival — 8; 7 Months

Primary: Number of Participants With a Partial Response — 2; 0 Participants

Primary: Objective Response Rate (Complete and Partial Response) — 26.7; 9.1 percentage of participants

Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants

Primary: Time to Participant Recovery — 6; 12 days

Primary: Response Rate — 0; 0; 26; 11 Participants

Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months

Primary: Net Change Relative to Baseline in Tumor Blood Flow — -0.44; -0.12; -0.60; -0.40 ml/min/100gm

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: Maximum Tolerated Dose (MTD) — 20 mg/kg

Primary: Progression-free Survival — 8.3 months

Primary: To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy. — 25…

Primary: Maximum Tolerated Dose (MTD) — 300 mg